Indication
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. Ivemend 150 mg is given as part of a combination therapy.
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- Ivemend 150 MG Polvo Para Solucion Para PerfusionSpain · 150 mg · polvo para solución para perfusión · Merck Sharp & Dohme B.V.Same brand
- IvemendCroatiaSame brand
- Ivemend 150 mg poeder voor oplossing voor infusieNetherlands · Poeder voor oplossing voor infusie · Merck Sharp & Dohme B.V.Same brand
- Emend InjetávelBrazil · Merck Sharp & Dohme Farmaceutica Ltda.